TECH Stock Recent News

MINNEAPOLIS , Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025.

MINNEAPOLIS , Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million.

MINNEAPOLIS , Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar.

ST. PAUL, Minn. , Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant.

TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.

ST. PAUL, Minn. , July 31, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that three investigators at the University of Minnesota's Center for Genome Engineering have been awarded $665,000 of G-Rex® Grant funding.

Bio-Techne Corporation is a market leader in life science reagents, well positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in. My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.

Antwerp, July 17, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) provides a market update on the progress of the stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) ("Golden Ocean"). The transaction is structured as a merger, with Golden Ocean merging with and into CMB.TECH Bermuda Ltd.

MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?